Xavier Parreno, MD
Internal Medicine · Gurnee, ILNPI 1023085479
Payments from drug & device makers
Across 1,607 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Novo Nordisk$3K
- Boehringer Ingelheim$3K
- Amgen$3K
- AbbVie$2K
- Lilly USA, LLC$2K
- plus $19K from 46 others
What the payments were for
- Consulting fees$8962%
- Speaking & faculty fees$140%
- Food & beverage$36,13096%
- Education$6792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,719 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 256 | $213,620 |
| FarxigaDapagliflozin Propanediol | 231 | $184,058 |
| OzempicSemaglutide | 113 | $124,083 |
| VascepaIcosapent Ethyl | 188 | $101,677 |
| TrulicityDulaglutide | 73 | $96,644 |
| LinzessLinaclotide | 131 | $92,243 |
| EliquisApixaban | 84 | $73,092 |
| JanuviaSitagliptin Phosphate | 64 | $71,323 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $50,497 |
| TradjentaLinagliptin | 60 | $48,641 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $41,445 |
| GemtesaVibegron | 49 | $39,394 |
| Repatha SureclickEvolocumab | 38 | $31,934 |
| Praluent PenAlirocumab | 52 | $31,107 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $30,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $2,667 | $262,261316 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $5,652 | $214,190273 claims |
| Novo NordiskOzempic | $3,259 | $124,083113 claims |
| AbbVieLinzess, Ubrelvy | $2,411 | $115,242145 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $2,103 | $113,09089 claims |
| PfizerEliquis, Nurtec Odt | $1,449 | $91,55996 claims |
| MerckJanuvia | $719 | $71,32364 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,287 | $58,42288 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $339 | $39,39449 claims |
| Astellas Pharma US IncMyrbetriq | $565 | $22,64734 claims |
| NovartisEntresto | $504 | $21,62733 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,582 | $20,97415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Gurnee
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.